Candidemia Clinical Trial
Official title:
Early- and Late-onset Candidemia: A Retrospective Study
A timing diagnosis of candidemia is as important as the correct choice of empiric or
targeted antifungal therapy. In the last years a growing body of knowledge has better
characterized health-care associated (HCA) infections, which have been described in 2002 in
outpatients with MRSA bloodstream infections. So far there is no compelling evidence that
patients with HCA infections may develop candidemia before the usual timing of around 20-25
days after admission. Risk factors associated with HCA infections are represented by
admission from long term chronic care facilities (LTCF), haemodialysis, previous admission
or parenteral broad spectrum antibiotics. There are few data HCA features and early onset
candidemias in the published literature.
In this proposal, the investigators aim at studying early-onset candidemia in a
retrospective study in one of the largest referral hospital in Italy with a consistent range
of specialties ranging (bone marrow transplant, solid organ transplant, immunosuppressed
patients, ICU, complex surgery). The investigators speculate that patients with candidemia
diagnosed within 10 days (early-onset) by the admission have different risk factors and
prognosis of those with a late diagnosis.
n/a
Observational Model: Cohort, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01982071 -
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
|
Phase 4 | |
Completed |
NCT02163889 -
Serial Therapeutic and Antifungal Monitoring Protocol
|
||
Completed |
NCT02244606 -
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
|
Phase 2 | |
Recruiting |
NCT01438216 -
Anidulafungin Pharmacokinetics in Intensive Care Unit Patients
|
N/A | |
Not yet recruiting |
NCT01249313 -
Risk Factor and Outcome of Candidemia
|
N/A | |
Terminated |
NCT01213823 -
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
|
Phase 4 | |
Completed |
NCT00940017 -
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
|
Phase 4 | |
Completed |
NCT00105144 -
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
|
Phase 3 | |
Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
Completed |
NCT03604705 -
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
|
Phase 2 | |
Completed |
NCT00607763 -
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
Completed |
NCT00608335 -
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
Recruiting |
NCT04147975 -
Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
|
||
Completed |
NCT01734525 -
Negative Beta Glucan in ICU Patients
|
Phase 4 | |
Withdrawn |
NCT01622595 -
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
|
N/A | |
Completed |
NCT03363841 -
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
|
Phase 3 | |
Completed |
NCT03799172 -
Echinocandins Versus Azoles for Candidemia Treatment
|
||
Completed |
NCT00670657 -
CRITIC - Treatment of Candidemia and Invasive Candidiasis
|
Phase 4 | |
Completed |
NCT00113191 -
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
|
N/A | |
Recruiting |
NCT04368559 -
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
|
Phase 3 |